Ozempic’s Dark Side: 45% Increased Risk of Suicidal Ideation

Alarming Spike in Suicide Risk Tied to Ozempic Use

Individuals with pre-existing mental health conditions may be particularly vulnerable to semaglutide’s psychological side effects. When the analysis focused on patients also taking antidepressants or antianxiety medications, the risk of suicidal ideation was even higher — a 150% to 300% increase in suicidal ideation was found among this group.³

“People with anxiety and depressive disorders may be at higher probability of reporting suicidal ideation when medicated with semaglutide,” the researchers noted.⁴ The drug’s clinical trials often excluded patients with recent major depressive episodes or severe psychiatric disorders. As a result, the full extent of its impact on mental health in vulnerable populations remains unknown.

The popularity of semaglutide has led to widespread off-label use and shortages, and a significant number of reported adverse events involved possible off-label prescriptions. Social media has further fueled its popularity as a lifestyle drug, with many seeking it solely for weight loss.

This trend has even led to illegal trade in semaglutide pens, some of which are counterfeit, posing additional risks to unsuspecting users. “Considering the risk of suicidal ideation in people taking semaglutide off-label, authorities should consider issuing a warning to inform about this risk,” the authors stated.⁵

Suicide: The Weight Loss Wonder Drug’s Sinister Secret

The featured study is not the first time Ozempic has raised red flags about suicide. The Icelandic Medicines Agency received multiple reports of suicidal thoughts and self-injury in people using semaglutide, prompting the European Medicines Agency (EMA) to begin reviewing the connection in July 2023.⁶

With more than 20 million people taking semaglutide and liraglutide, a GLP-1 agonist medication similar to semaglutide, annually, the implications could be devastating to public health.⁷ “Previously, in the approval trials, 9 of the 3384 patients treated with liraglutide (0.27%) had reported suicidal ideation compared with 2 of 1941 patients allocated to the placebo group (0.10%),” researchers explained.⁸

Since then, the British Medicines and Healthcare Products Regulatory Agency and the U.S. Food and Drug Administration (FDA) have started similar investigations. The study authors explained, however, that the FDA appears to have known about the suicide risk for some time:⁹

“Although EMA stated that no update to the product information is warranted, based on these findings, we believe that a precaution of use in patients with psychiatric disorders or psychological lability could be added in the semaglutide package insert. Remarkably, the FDA label of semaglutide for obesity warned to monitor for depression or suicidal thoughts.”

Wegovy Users at Risk of Suicidal Thoughts

As Ozempic and similar GLP-1 receptor agonist drugs (GLP-1 RAs) continue to gain popularity for weight loss, a pharmacovigilance study examined 209,354 adverse event reports for these medications, finding a troubling association with suicidal thoughts and self-harm.¹⁰

The analysis revealed higher rates of psychiatric issues, particularly for liraglutide (Saxenda), semaglutide (Wegovy) and tirzepatide. So, while the drugs can lead to rapid weight loss, they may paradoxically increase suicide risk in some individuals. Researchers wrote in European Neuropsychopharmacology:¹¹

“Notably, the U.S. prescribing information for liraglutide 3.0 mg already recommends vigilant monitoring for depression or suicidal thoughts, emphasizing discontinuation if these symptoms manifest. Similarly, a parallel cautionary note is present in the U.S. prescribing information for the semaglutide formulation Wegovy®, being administered at higher dosages for weight control than for T2DM [Type 2 diabetes].”

GLP-1 receptors are present in brain regions involved in mood regulation. By altering neurotransmitter systems and reward pathways, these medications could trigger depression or exacerbate existing mental health conditions.

Further, they suggested, “One could wonder if the putative suicidal risk associated with GLP-1 RA may be tied to their impact on the hypothalamus, considering the established association between the hyperactivity of the hypothalamic-pituitary-adrenal axis and the occurrence of suicidal behaviors.”¹²

Alarming Rates of Suicidal Thoughts with Newer GLP-1 Drugs

Analysis of the European Pharmacovigilance Database also revealed concerning patterns regarding semaglutide and liraglutide.¹³ Out of 41,236 adverse event reports for these drugs, 230 involved suicidal events — a small but significant number. Liraglutide and semaglutide accounted for the majority, with 88 and 84 cases respectively.

Notably, 68% of liraglutide reports and 13% of semaglutide reports were specifically linked to the higher-dose weight loss formulations. The data showed these newer drugs had two to four times higher odds of suicidal event reports compared to older GLP-1 drugs.

While the absolute numbers are low, this disproportionate reporting is troubling. Most cases involved women aged 18 to 64, with suicidal thoughts being most common. There were 14 fatal outcomes. If you’re considering or using these medications, it’s crucial to be aware of this significant risk.

The precise reasons for increased suicidal thoughts with GLP-1 drugs remain unclear, but their effects on neurotransmitter systems like serotonin may play a role. Additionally, rapid weight loss itself can trigger psychological changes, while underlying conditions like diabetes and obesity are also associated with higher suicide risk, complicating the picture.

European product information for these drugs doesn’t yet include warnings about suicidal thoughts, underscoring the importance of real-world safety monitoring beyond clinical trials.

Weight Loss Drugs Linked to Severe Psychiatric Issues, Suicide Deaths

Ozempic and similar GLP-1 receptor agonist medications continue to be hailed as game-changers for weight loss and diabetes management despite their suicide connection. An additional pharmacovigilance analysis of the EudraVigilance database revealed yet another troubling link between these drugs and psychiatric adverse events.¹⁴

The study examined reports for semaglutide, liraglutide, and tirzepatide from January 2021 to May 2023. Out of 31,444 total adverse event reports, 372 (1.18%) were related to psychiatric issues. While this percentage may seem small, the severity of these events is alarming.

Depression topped the list at 50.3% of psychiatric reports, followed by anxiety (38.7%) and suicidal ideation (19.6%). Most disturbingly, nine deaths were reported, with eight linked to liraglutide and one to semaglutide. These fatalities were primarily due to completed suicides, predominantly affecting men aged 18 to 64.

The study uncovered 102 adverse events related to suicide, ranging from ideation to completed acts. Semaglutide accounted for half of these events, while liraglutide was associated with 47%. Even the newer medication tirzepatide, despite fewer overall reports, showed a similar proportion of suicidal events.

Women reported 62% of these incidents, with nearly half occurring in the 18 to 64 age group. This data paints a stark picture of the potential mental health risks associated with these popular weight loss drugs, and the severity of the reported events demands serious attention and further investigation.

Exploring the Neurobehavioral Effects of Semaglutide

Separate research has uncovered additional concerning connections between semaglutide and brain function.¹⁵ GLP-1 receptors, the targets of drugs like Ozempic, are found in brain regions involved in emotion regulation. Animal studies have shown that GLP-1 agonists can initially induce anxiety, which may subside with continued use. However, the long-term impacts on human brain chemistry remain unclear.

Your brain’s delicate balance of neurotransmitters could be affected by these medications, leading to mood changes. While some patients report improved mood and reduced depressive symptoms with weight loss, others experience the opposite effect. This variability highlights the complex interplay between semaglutide, brain function and individual neurochemistry.

In a case study of a 54-year-old woman, doctors suspected semaglutide was responsible for depressive symptoms, which disappeared when the drug was discontinued:¹⁶

“After four weeks of treatment with semaglutide, the patient reported feeling more irritable and anxious than usual. She also experienced difficulty sleeping and a loss of interest in activities she previously enjoyed. These symptoms persisted over the next two weeks and began to interfere with her daily life. We suspected that her negative mood changes were consistent with major depressive syndrome.

… Given her worsening depressive symptoms, which temporally correlated with starting on semaglutide, we decided to discontinue semaglutide and switch her to a different medication. Over the next several weeks, the patient’s mood symptoms improved, and she reported feeling more like herself again.”

Understanding the Mechanism: How Ozempic Affects Your Mood

Research published in Frontiers in Psychiatry has shed light on how semaglutide could influence your mood and mental health.¹⁷ As mentioned, the drug’s active ingredient targets GLP-1 receptors, which are found not only in your digestive system but also in key areas of your brain. These brain regions, including the lateral septum and hypothalamus, play crucial roles in regulating mood, reward, and food intake.

When semaglutide interacts with these receptors, it can alter the activity of neural pathways involved in these processes. Of particular interest is its effect on dopamine, a neurotransmitter closely linked to mood and reward. Studies suggest that GLP-1 receptor stimulation can increase dopamine transporter expression, reducing free dopamine levels in certain brain areas.

This alteration in dopamine signaling could contribute to changes in mood, motivation and even the experience of pleasure. If you’re considering Ozempic, it’s important to understand that its effects extend beyond appetite suppression and weight loss, impacting your brain chemistry in ways that scientists are still working to fully understand.

Real-World Experiences with Semaglutide-Associated Depression

Two additional case studies highlight semaglutide’s ability to trigger or exacerbate depression in some individuals.¹⁸ In one case, a 54-year-old man with no prior history of mood disorders developed depressive symptoms about a month after starting semaglutide for weight loss. He experienced fatigue, decreased interest and motivation, and difficulty concentrating.

Importantly, his symptoms improved significantly within days of discontinuing the medication. In another case, a 40-year-old woman with a history of recurrent depression experienced a severe relapse about a month after adding semaglutide to her diabetes treatment. Her symptoms, including suicidal ideation, also improved after stopping the medication.¹⁹

Mental Health Risks and Suicidal Thoughts

People using Ozempic and other GLP-1 RAs also reported severe psychiatric side effects in a study published in Brain Sciences.²⁰ One user warned, “Ozempic can cause suicidal thoughts … Anxiety, Panic Attacks, Suicidal thoughts, etc. Not all people will experience this side effect, but please remember that if you do feel you are depressed, more anxious, etc., please check your medication.”²¹

Many users also reported new or worsened anxiety after starting Ozempic. One individual described “crazy anxiety” after increasing their dose. Another experienced “severe anxiety, constant panic attacks, insomnia, hypoglycemia.” Some users found their existing mental health conditions exacerbated, with reports of increased irritability, mood swings and even manic episodes.²²

One user shared, “This IMMEDIATELY threw my hormones and emotions into a downward spiral. I’m infuriated that they don’t list anxiety and depression as an official side effect yet it’s all over the internet.”²³

Another user recounted, “Within a few weeks, I was so depressed, I wasn’t leaving my room, or spending time with my kids. I did the bare minimum.” Another stated, “Yep it gave me the worst anxiety and depression. I had no choice to get off it after 5 kg weight loss only. Life was not worth living at that point.”²⁴

Weight Loss with Ozempic Could Wreck Your Health

Along with suicidal ideation, Ozempic and similar medications are also linked to a number of other side effects, including serious gastrointestinal issues. Research from the University of British Columbia revealed that GLP-1 agonists are associated with an increased risk of stomach paralysis, pancreatitis, and bowel obstruction.²⁵ A study of 25,617 people also found use of GLP-1 agonists increases the rate of intestinal obstruction by 3.5-fold.²⁶

In other cases, those who have taken the injections experience life-changing side effects making them wish they never touched the drugs. Joanne Knight had been taking Ozempic for about two years when she became unable to swallow food.²⁷ The reason? Her stomach was full of food. Violent vomiting and constant nausea followed, along with a diagnosis of severe gastroparesis, or stomach paralysis.

Meanwhile, reports underscore the drug’s effects on facial fat — when too much fat is lost from your face, it can lead to a gaunt appearance, dubbed “Ozempic face.” An article in Plastic and Reconstructive Surgery — Global Open²⁸ highlights that similar changes can also occur elsewhere in your body, including leading to deflated breasts and backside, conditions now known as “Ozempic breast” and “Ozempic butt.”

Ozempic Linked to Vision Loss

A Danish-Norwegian cohort study has revealed another reason to reconsider Ozempic — it’s linked to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION).²⁹

NAION is a serious condition that leads to sudden, painless vision loss in one eye. It occurs when blood flow to the optic nerve is disrupted, causing damage that is often irreversible. While NAION is uncommon, its severe impact on vision makes any increase in risk a matter of concern for those using medications like Ozempic.

The study, which analyzed data from national health registries in Denmark and Norway, compared new users of Ozempic with those taking sodium-glucose co-transporter 2 inhibitors (SGLT-2is), another class of diabetes medication. Researchers aimed to determine whether there was an association between Ozempic use and the incidence of NAION. They included 44,517 Ozempic users in Denmark and 16,860 in Norway, monitoring them for up to five years.

Findings from the study indicated that individuals using Ozempic had a higher risk of developing NAION compared to those on SGLT-2is. Specifically, the pooled hazard ratio was 2.81, meaning there was almost a threefold increase in risk. However, the absolute risk, which refers to the actual number of additional cases per 10,000 person-years, was relatively low — about 1.41 extra cases among Ozempic users.

That being said, the study’s results were consistent across various analyses, reinforcing the reliability of the association. The findings also back up an earlier Harvard University study, which also linked Ozempic with NAION. This matched cohort study evaluated 16,827 patients and revealed a pronounced association between semaglutide prescriptions and the onset of NAION.³⁰

In this study, patients with Type 2 diabetes and those who were overweight or obese were closely monitored. Individuals prescribed semaglutide exhibited a hazard ratio of 4.28 for developing NAION in the diabetes cohort and an even higher hazard ratio of 7.64 in the overweight or obese group. These figures suggest that semaglutide users were over four to seven times more likely to experience NAION compared to those on other treatments.

The temporal association observed — where the risk of NAION peaked within the first year of semaglutide initiation — adds weight to the argument that the medication plays a direct role in the development of this serious eye condition. Combining insights from both studies paints a concerning picture — there appears to be a consistent link between semaglutide use and an increased risk of NAION that cannot be ignored.

Sources and References
1,2 4, 5, 7, 8, 9 – JAMA Netw Open. 2024;7(8):e2423385
3 – ZeroHedge August 21, 2024
6 – European Medicines Agency July 11, 2023
10, 11 – European Neuropsychopharmacology, Volume 82, May 2024, Pages 82-91
12 – European Neuropsychopharmacology, Volume 82, May 2024, Pages 82-91, Discussion
13 –  Pharmaceuticals (Basel). 2024 Jan 23;17(2):147
14 –  Int J Clin Pharm. 2024 Jan 24;46(2):488–495
15, 16 -Innov Clin Neurosci. 2024 Jun 1;21(4-6):25–26
17, 18, 19 – Front Psychiatry. 2023 Aug 29;14:1238353
20, 21, 22, 23, 24 – Brain Sci. 2023 Oct 24;13(11):1503
25 – JAMA. 2023;330(18):1795-1797 doi:10.1001/jama.2023.19574
26 – Acta Pharmaceutica Sinica B, Volume 13, Issue 5, May 2023, Pages 2291-2293

27 – CNN Health July 25, 2023
28 – Plast Reconstr Surg Glob Open. 2024 Jan 24;12(1):e5516
29 – medRxiv, December 11, 2024, doi: 10.1101/2024.12.09.24318574
30 – JAMA Ophthalmol. 2024;142(8):732-739